Company Announcement No. 53/2024
Transactions in Zealand Pharma (NASDAQ:) shares and/or related securities by persons carrying out management responsibilities and/or persons closely associated with them
Copenhagen, Denmark, December 25, 2024 “ Zealand Pharma A/S (New Zealand) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received transaction information in shares of Zealand Pharma or related securities managed by persons with management responsibilities and/or persons closely associated with them, and hereby publishes information relating to such transactions.
Please see the attached file(s).
About Zealand Pharma A/S
Zeeland Pharma A/S (Nasdaq: ZEAL) (“Zeeland”) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 New Zealand-invented drug candidates have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnership agreements with a number of pharmaceutical companies, in addition to commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand's business and activities, please visit the following website: www.zealandpharma.com.
communication:
Nashat Ahmadi (Investors)
Investor Relations Manager
Email: neahmadi@zealandpharma.com
Adam Lange (Investors)
Investor Relations Officer
Email: alange@zealandpharma.com
Anna Krasowska, Ph.D. (Media and Investors)
Vice President of Investor Relations and Corporate Communications
Email: akrassowska@zealandpharma.com
- 20241225 – Leonard Croemer – Buy shares
